RE: Nothing shifts the needle2 Jul 2022 14:37
It’s a poor piece of research beza, IMO... 1) they are too pessimistic about dividend reinstatement because they assume the actuarial deficit and related payments are fixed ad infinitum, when in fact they are reviewed every 3 years. The level of actuarial liabilities are highly sensitive to the discount rate - the IAS liabilities sensitivity for example is 16% for every 1% move in the discount rate. Using March 2021 data, the prelim actuarial assessment estimated the liabilities at around £250m, but since then the discount rate has moved from 2%, to around 4%. Taken on it own this would suggest a circa 30% or £75m reduction in the liability, nearly the entire actuarial deficit. A materially lower deficit would likely mean materially lower pension payments. Of course, this will likely not help much with the payments review to be completed in July, but does suggest that dividend payments may be reinstated long before the “decade” that small caps life believe is a clear inevitability.. 2) small caps life are wrong to state that using a PE is inappropriate for an indebted company. The EPS used in the PE calculation is AFTER interest paid, meaning the measure does adjust for interest paid and consequently the scale of debt… 3) small caps life have miscalculated their earnings yield. They state that even assuming 30% EPS growth gets them to a 3.8% earnings yield for next year. In fact, the reported underlying EPS from the year just reported was 3.1p, and adding 30% gets you to 4p. At a share price of 22p, this results in an earnings yield of 18.1%, far higher than the 3.8% small caps life state… in short, be careful taking anything small caps life tell you at face value, sounds like poor quality stuff.. ATB